BMRN BioMarin Pharmaceutical Inc. Stock Quote

BMRN [NASD]

Index	-	P/E	-	EPS (ttm)	-0.03	Insider Own	0.40%	Shs Outstand	181.44M	Perf Week	0.23%
Market Cap	14.44B	Forward P/E	77.76	EPS next Y	1.01	Insider Trans	-10.69%	Shs Float	180.42M	Perf Month	-0.20%
Income	-3.30M	PEG	-	EPS next Q	-0.10	Inst Own	-	Short Float	6.21%	Perf Quarter	-3.56%
Sales	1.86B	P/S	7.76	EPS this Y	117.90%	Inst Trans	1.01%	Short Ratio	9.35	Perf Half Y	-2.03%
Book/sh	22.63	P/B	3.46	EPS next Y	324.40%	ROA	15.60%	Target Price	107.11	Perf Year	-8.77%
Cash/sh	5.77	P/C	13.55	EPS next 5Y	32.16%	ROE	23.50%	52W Range	71.35 - 131.95	Perf YTD	-10.79%
Dividend	-	P/FCF	-	EPS past 5Y	15.10%	ROI	0.20%	52W High	-40.71%	Beta	0.59
Dividend %	-	Quick Ratio	3.30	Sales past 5Y	15.90%	Gross Margin	71.80%	52W Low	9.64%	ATR	1.79
Employees	3059	Current Ratio	4.80	Sales Q/Q	-0.50%	Oper. Margin	-2.00%	RSI (14)	51.92	Volatility	1.96% 2.17%
Optionable	Yes	Debt/Eq	0.26	EPS Q/Q	-359.90%	Profit Margin	46.20%	Rel Volume	0.55	Prev Close	77.77
Shortable	Yes	LT Debt/Eq	0.26	Earnings	Feb 25 AMC	Payout	0.00%	Avg Volume	1.20M	Price	78.23
Recom	2.00	SMA20	1.62%	SMA50	-1.82%	SMA200	-10.72%	Volume	664,708	Change	0.59%

Mar-04-21

Resumed

Guggenheim

Buy

Mar-01-21

Upgrade

Evercore ISI

In-line → Outperform

$90 → $100

Aug-20-20

Downgrade

William Blair

Outperform → Mkt Perform

Aug-20-20

Downgrade

Citigroup

Buy → Neutral

$148 → $86

Aug-19-20

Downgrade

Stifel

Buy → Hold

$127 → $100

Aug-19-20

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

Aug-19-20

Downgrade

Evercore ISI

Outperform → In-line

Jul-08-20

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$125

Jul-06-20

Reiterated

Citigroup

Buy

$105 → $148

Jan-28-20

Initiated

BMO Capital Markets

Market Perform

Jan-27-20

Initiated

BMO Capital Markets

Market Perform

Jan-24-20

Upgrade

RBC Capital Mkts

Sector Perform → Outperform

$111 → $113

Nov-27-19

Upgrade

Barclays

Equal Weight → Overweight

$86 → $98

Nov-12-19

Initiated

SunTrust

Buy

$110

Oct-17-19

Resumed

BofA/Merrill

Buy

$90

May-23-19

Resumed

Citigroup

Buy

Apr-09-19

Resumed

Raymond James

Outperform

Jan-02-19

Downgrade

Raymond James

Outperform → Mkt Perform

Dec-14-18

Initiated

Wolfe Research

Outperform

Oct-01-18

Initiated

Cantor Fitzgerald

Overweight

$126

Apr-13-21 08:30AM	BioMarin to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, April 29 at 4:30pm ET PR Newswire
Mar-30-21 01:23PM	Replay: Investing in Alzheimers Treatment Jupiter Orphan Therapeutics CEO Joins Fireside Chat IPO-Edge.com
Mar-27-21 11:31AM	BioMarin (BMRN) Down 7.7% Since Last Earnings Report: Can It Rebound? Zacks
Mar-23-21 01:53PM	Investing in Alzheimers Treatment: Join Jupiter Orphan Therapeutics for Fireside Chat March 30 IPO-Edge.com
Mar-21-21 10:02PM	Is BioMarin (BMRN) Stock A Buy or Sell? Insider Monkey
Mar-20-21 11:15AM	BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society's Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide PR Newswire
Mar-19-21 10:50PM	BIOMARIN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN Business Wire
Mar-12-21 11:29AM	7 Pharmaceutical Stocks Working on Their Next Blockbuster InvestorPlace
Mar-09-21 09:05AM	BioMarin (BMRN) Hemophilia Gene Therapy Gets FDA's RMAT Tag Zacks
Mar-08-21 12:05PM	BioMarin's Hemophilia Gene Therapy Scores RMAT Designation In US Benzinga
08:31AM	BioMarin Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A PR Newswire
Mar-03-21 08:31AM	BioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia PR Newswire
Feb-26-21 10:50PM	BIOMARIN INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN PR Newswire -5.30%
12:02PM	Biomarin Pharmaceutical Inc (BMRN) Q4 2020 Earnings Call Transcript Motley Fool
09:16AM	BioMarin (BMRN) Q4 Earnings Beat, 2021 Sales View Dull Zacks
Feb-25-21 02:30PM	BioMarin Pharmaceutical, Inc. to Host Earnings Call ACCESSWIRE
Feb-24-21 10:09AM	Biomarin Pharmaceutical's Earnings Outlook Benzinga
08:30AM	BioMarin to Participate in Four Upcoming Virtual Investor Conferences PR Newswire
Feb-18-21 04:01PM	BioMarin Appoints Former Goldman Sachs Partner and Life Sciences Executive, Maykin Ho, Ph.D. to Board of Directors PR Newswire
Feb-11-21 11:40AM	ALXN vs. BMRN: Which Stock Is the Better Value Option? Zacks
Feb-06-21 01:52AM	Should BioMarin Pharmaceutical (NASDAQ:BMRN) Be Disappointed With Their 22% Profit? Simply Wall St.
Jan-28-21 09:00AM	BioMarin Earns Top Marks in Human Rights Campaign's 2021 Corporate Equality Index PR Newswire
Jan-26-21 11:40AM	ALXN vs. BMRN: Which Stock Should Value Investors Buy Now? Zacks
08:30AM	BioMarin to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, February 25 at 4:30pm ET PR Newswire
Jan-22-21 07:55AM	Is Now A Good Time To Buy BioMarin Stock? Motley Fool
Jan-15-21 10:50PM	BIOMARIN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN Business Wire
Jan-12-21 09:24AM	Stock Market News for Jan 12, 2021 Zacks
Jan-11-21 10:58AM	BioMarin's stock tumbles 6% after sharing data about experimental hemophilia A drug MarketWatch -9.59%
10:14AM	BioMarins One-Year Data on Its Hemophilia Gene-Therapy Looked Good. Can It Win FDA Approval? Barrons.com
08:37AM	BioMarin (BMRN) Reveals 1-Year Data on Hemophilia Gene Therapy Zacks
08:11AM	Gene-Therapy Firm Bluebird Bio Is Spinning Off Its Cancer Programs Barrons.com
Jan-10-21 06:44PM	BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set PR Newswire
Jan-07-21 11:40AM	ALXN or BMRN: Which Is the Better Value Stock Right Now? Zacks
Jan-05-21 08:30AM	BioMarin to Participate in Two Upcoming Virtual Investor Conferences PR Newswire
Jan-04-21 08:42AM	Is BioMarin Pharmaceutical (BMRN) Stock a Buy For 2021? Insider Monkey
Dec-31-20 09:24AM	Is BioMarin Pharmaceutical (BMRN) a Smart Long-term Buy? Insider Monkey
Dec-21-20 08:29AM	BioMarin Announces Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study PR Newswire
Dec-18-20 12:14PM	The Zacks Analyst Blog Highlights: BioMarin Pharmaceutical, uniQure, REGENXBIO and Deciphera Pharmaceuticals Zacks
Dec-17-20 04:21PM	12 Best Large Biotech Stocks to Buy Now Insider Monkey
09:42AM	4 Biotechs That Could Be Potential Acquisition Targets in 2021 Zacks
Dec-14-20 01:38PM	Is BMRN A Good Stock To Buy Now? Insider Monkey
Dec-09-20 04:02PM	Top Biotech Stocks for Q1 2021 Investopedia
Dec-05-20 11:32AM	Why Is BioMarin (BMRN) Up 6.1% Since Last Earnings Report? Zacks
Dec-01-20 08:30AM	BioMarin to Participate in Two Upcoming Virtual Investor Conferences PR Newswire
Nov-24-20 03:35PM	SHAREHOLDER ALERT: BMRN RCL LOOP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
03:00PM	BMRN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Investors of Class Action and Deadline: November 24, 2020 ACCESSWIRE
11:39AM	Pfizer (PFE) Begins Phase III Study on Hemophilia Candidate Zacks
10:15AM	Lawsuits Filed Against BMRN, BIIB and YY - Jakubowitz Law Pursues Shareholders Claims ACCESSWIRE
10:00AM	BMRN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: November 24, 2020 GlobeNewswire
09:53AM	FINAL DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Reminds BioMarin Pharmaceutical Inc. Investors of Important November 24 Deadline in Securities Class Action - BMRN Newsfile
09:13AM	DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm Business Wire
06:20AM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of BMRN, CACC and TRQ ACCESSWIRE
Nov-23-20 10:50PM	BIOMARIN 24 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN PR Newswire
05:40PM	LAWSUITS FILED AGAINST BMRN, HPQ and YY - Jakubowitz Law Pursues Shareholders Claims ACCESSWIRE
04:10PM	FINAL DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
01:27PM	BMRN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of November 24, 2020 in the Class Action Filed on Behalf of BioMarin Pharmaceutical Inc. Limited Shareholders Newsfile
12:00PM	DEADLINE ALERT for GTX, GTXMQ, BMRN, BTU, PT: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
12:00PM	BMRN FINAL DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Reminds BioMarin Pharmaceutical Inc. Investors of Important Tuesday Deadline in Securities Class Action BMRN GlobeNewswire
11:00AM	DEADLINE ALERT for WRTC, GLNG, GTX, GTXMQ, and BMRN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
11:00AM	BMRN Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Investors WIth Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: November 24, 2020 ACCESSWIRE
10:15AM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of BMRN, GTX and LRN ACCESSWIRE
09:39AM	DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Newsfile
06:32AM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of BioMarin Pharmaceutical Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 24, 2020 - BMRN Newsfile
Nov-22-20 10:50PM	BIOMARIN 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN Business Wire
01:00PM	BMRN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Investors of Class Action and Deadline: November 24, 2020 ACCESSWIRE
Nov-21-20 07:00AM	IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
Nov-20-20 10:50PM	BIOMARIN 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN Business Wire
07:50PM	CLASS ACTION UPDATE for BMRN, BTU and LRN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
07:09PM	BMRN FINAL DEADLINE: ROSEN, A RESPECTED LAW FIRM, Reminds BioMarin Pharmaceutical Inc. Investors of Important Tuesday Deadline in Securities Class Action - BMRN Newsfile
01:00PM	SHAREHOLDER ALERT: BMRN ACB ICPT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
01:00PM	BMRN Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Shareholders of Class Action and Lead Plaintiff Deadline: November 24, 2020 Newsfile
11:30AM	The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioMarin Pharmaceuticals Inc. (BMRN) Business Wire
11:20AM	TUESDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Newsfile
11:00AM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of GOCO, BMRN and TRQ ACCESSWIRE
09:33AM	Nasdaq-100 Laggards Could Offer Timely Short Sales Investopedia
08:00AM	BioMarin Pharmaceutical, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit: Portnoy Law Firm GlobeNewswire
Nov-19-20 06:09PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of BioMarin Pharmaceutical Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 24, 2020 - BMRN Newsfile
04:40PM	SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
04:37PM	Uniqure Hits Pay Dirt In Gene Therapy And The Biotech Stock Bounds Higher Investor's Business Daily
01:57PM	BMRN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of November 24, 2020 in the Class Action Filed on Behalf of BioMarin Pharmaceutical Inc. Limited Shareholders Newsfile
12:30PM	Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioMarin Pharmaceuticals, Inc. (BMRN) GlobeNewswire
12:15PM	LAWSUITS FILED AGAINST GLNG, BMRN and ZSAN - Jakubowitz Law Pursues Shareholders Claims ACCESSWIRE
11:08AM	BMRN ALERT NOV. 24 DEADLINE - Pawar Law Group Announces a Securities Class Action Lawsuit Against BioMarin Pharmaceutical Inc. GlobeNewswire
11:00AM	BMRN Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Shareholders of Class Action and Lead Plaintiff Deadline: November 24, 2020 Business Wire
10:30AM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of GLNG, BMRN and GTX ACCESSWIRE
09:49AM	TUESDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Newsfile
06:20AM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BMRN, CACC and LVS ACCESSWIRE
Nov-18-20 11:18PM	ROSEN, GLOBAL INVESTOR COUNSEL, Reminds BioMarin Pharmaceutical Inc. Investors of Important November 24 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - BMRN PR Newswire
10:50PM	SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BMRN, BTU, CACC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits GlobeNewswire
03:28PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of BioMarin Pharmaceutical Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 24, 2020 - BMRN Newsfile
02:00PM	NOVEMBER 4 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
11:30AM	CLASS ACTION UPDATE for BMRN, MESO and LOOP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
11:00AM	GLNG & BMRN Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Upcoming Lead Plaintiff Deadlines GlobeNewswire
06:20AM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BMRN, CACC and FAF ACCESSWIRE
Nov-17-20 10:50PM	FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BMRN, BTU and RTX GlobeNewswire
02:58PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of BioMarin Pharmaceutical Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 24, 2020 - BMRN Newsfile
01:30PM	FINAL DEADLINE IMMINENT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
12:30PM	CLASS ACTION UPDATE for FLDM, BMRN and LVS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
11:45AM	DEADLINE ALERT for WRTC, GLNG, GTX, GTXMQ, and BMRN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
11:00AM	GLNG & BMRN Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Upcoming Lead Plaintiff Deadlines ACCESSWIRE

BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; BMN 307, an AAV5 mediated gene therapy, which is in phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; BMN 331 for the treatment of hereditary angioedema; BMN 255 for the treatment of chronic renal disease; and BMN 351 for the treatment of Duchenne Muscular Dystrophy. The company has collaboration and license agreements with Sarepta Therapeutics, Asubio Pharma Co., Ltd., and DiNAQOR AG. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. was incorporated in 1996 and is headquartered in San Rafael, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	Apr 08	Sale	78.81	1,537	121,131	58,250	Apr 09 05:57 PM
Mueller Brian	EVP, Chief Financial Officer	Apr 01	Sale	76.30	5,692	434,300	31,016	Apr 02 07:35 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	Mar 24	Sale	76.30	1,181	90,110	61,439	Mar 26 05:45 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	Mar 18	Sale	77.99	1,308	102,011	64,133	Mar 19 09:01 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Mar 12	Option Exercise	26.49	7,000	185,430	302,652	Mar 15 08:26 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Mar 12	Sale	77.10	7,000	539,700	295,652	Mar 15 08:26 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Mar 11	Option Exercise	26.49	7,000	185,430	302,652	Mar 15 08:26 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Mar 11	Sale	77.68	7,000	543,760	295,652	Mar 15 08:26 PM
GREY MICHAEL G	Director	Mar 05	Option Exercise	26.49	5,000	132,450	47,840	Mar 09 05:59 PM
GREY MICHAEL G	Director	Mar 05	Sale	76.28	5,000	381,400	42,840	Mar 09 05:59 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Feb 19	Option Exercise	26.49	7,000	185,430	302,552	Feb 22 08:38 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Feb 19	Sale	83.58	7,000	585,060	295,552	Feb 22 08:38 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Feb 18	Option Exercise	26.49	7,000	185,430	302,552	Feb 19 09:22 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Feb 18	Sale	85.08	7,000	595,560	295,552	Feb 19 09:22 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Feb 17	Option Exercise	26.49	8,000	211,920	303,552	Feb 18 09:45 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Feb 17	Sale	84.54	8,000	676,320	295,552	Feb 18 09:45 PM
LAWLIS V BRYAN	Director	Feb 16	Option Exercise	26.49	7,500	198,675	26,350	Feb 18 06:43 PM
LAWLIS V BRYAN	Director	Feb 16	Sale	87.41	7,500	655,575	18,850	Feb 18 06:43 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Jan 29	Option Exercise	26.49	8,334	220,768	303,886	Feb 01 07:00 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Jan 29	Sale	82.67	8,334	688,972	295,552	Feb 01 07:00 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Jan 28	Option Exercise	26.49	8,333	220,741	303,885	Feb 01 07:00 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Jan 28	Sale	82.91	8,333	690,889	295,552	Feb 01 07:00 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Jan 27	Option Exercise	26.49	8,333	220,741	303,885	Jan 28 07:35 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Jan 27	Sale	85.49	8,333	712,388	295,552	Jan 28 07:35 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Dec 29	Sale	88.18	1,500	132,270	295,552	Dec 30 08:02 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Dec 28	Sale	88.77	1,500	133,155	297,052	Dec 30 08:02 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	Oct 14	Sale	79.91	2,121	169,489	61,281	Oct 15 07:17 PM
HERON ELAINE J	Director	Oct 07	Option Exercise	26.49	15,000	397,350	66,968	Oct 08 08:35 PM
PYOTT DAVID E I	Director	Aug 31	Buy	78.26	12,800	1,001,715	30,740	Sep 01 09:44 PM
GREY MICHAEL G	Director	Aug 03	Option Exercise	26.49	2,500	66,225	45,340	Aug 05 06:56 PM
GREY MICHAEL G	Director	Aug 03	Sale	120.35	2,500	300,875	42,840	Aug 05 06:56 PM
FUCHS HENRY J	President, Worldwide R&D	Jul 20	Option Exercise	65.97	126,389	8,337,656	229,384	Jul 22 05:32 PM
FUCHS HENRY J	President, Worldwide R&D	Jul 20	Sale	130.00	126,389	16,430,570	102,995	Jul 22 05:32 PM
FUCHS HENRY J	President, Worldwide R&D	Jul 13	Option Exercise	65.97	23,011	1,518,094	126,006	Jul 15 09:32 PM
FUCHS HENRY J	President, Worldwide R&D	Jul 13	Sale	130.00	23,011	2,991,430	102,995	Jul 15 09:32 PM
Dere Willard H	Director	Jun 26	Sale	123.61	4,430	547,592	13,290	Jun 30 02:11 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	Jun 19	Option Exercise	63.10	15,000	946,500	78,402	Jun 23 07:24 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	Jun 19	Sale	124.00	15,000	1,860,000	63,402	Jun 23 07:24 PM
LAWLIS V BRYAN	Director	Jun 05	Sale	107.46	4,430	476,048	18,850	Jun 09 06:04 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 08	Option Exercise	21.51	20,000	430,200	318,552	May 12 01:51 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 08	Sale	91.72	20,000	1,834,400	298,552	May 12 01:51 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 04	Option Exercise	21.51	5,000	107,550	303,552	May 05 07:22 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 04	Sale	88.00	5,000	440,000	298,552	May 05 07:22 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 01	Option Exercise	21.51	4,000	86,040	302,552	May 05 07:22 PM
Davis George Eric	EVP, General Counsel	May 01	Sale	89.38	12,504	1,117,608	65,677	May 04 09:45 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 01	Sale	89.38	4,000	357,520	298,552	May 05 07:22 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Apr 28	Option Exercise	21.51	20,000	430,200	318,213	Apr 29 07:40 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Apr 28	Sale	97.58	20,000	1,951,600	298,213	Apr 29 07:40 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Apr 27	Option Exercise	21.51	20,000	430,200	318,213	Apr 29 07:40 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Apr 27	Sale	97.73	20,000	1,954,600	298,213	Apr 29 07:40 PM
FUCHS HENRY J	President, Worldwide R&D	Apr 24	Sale	95.88	20,000	1,917,617	102,656	Apr 28 02:37 PM
FUCHS HENRY J	President, Worldwide R&D	Apr 20	Sale	90.00	17,213	1,549,170	122,656	Apr 22 05:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience